PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37975903.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2580 and PMC identifier 10841812.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although dual HER2 inhibition has shown promising clinical activity in patients with RAS wild-type HER2-positive metastatic colorectal cancer, predictive biomarkers of response/resistance are less well characterized. Activating HER2/RTK/MAPK genomic alterations appears to blunt the clinical benefit of dual anti-HER2 therapy and may hold a potential albeit partial role in patient selection. See related article by Randon et al., p. 436.
Medical subject headings
- Erb-b2 Receptor Tyrosine Kinases
- Colorectal Neoplasms